A phase I clinical and pharmacokinetic study of capecitabine (Xeloda®) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours
暂无分享,去创建一个
V. Diéras | R. Guimbaud | P. Canal | E. Chatelut | F. Lokiec | J. Delord | R. Bugat | D. Mery-mignard | X. Cornen | I. Lochon | F. Turpin | F. Bertheault-Cvitkovic | Z. Mouri | J. Pierga